UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 612, 2026

Core Scientific, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-40046

86-1243837

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)


838 Walker Road, Suite 21-2105 Dover, Delaware						19904
(Address of principal executive offices)						(Zip Code)

Registrant’s telephone number, including area code: (512) 402-5233

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value $0.00001 per share	CORZ	The Nasdaq Global Select Market
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $6.81 per share	CORZW	The Nasdaq Global Select Market
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $0.01 per share	CORZZ	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 25.~~02 Results~~07. Submission of ~~Operations~~Matters ~~and~~to ~~Financial~~a ~~Condition~~Vote of Security Holders.

On May 6 12, 2026, Core Scientific, Inc. (the “Company”) ~~issued~~held aits ~~press~~2026 ~~release~~Annual ~~announcing~~Meeting ~~its~~of ~~financial~~Stockholders ~~results~~(the ~~for~~“Annual Meeting”). At the ~~first~~Annual ~~fiscal~~Meeting, ~~quarter~~the ~~ended~~stockholders ~~March 31,~~cast ~~2026~~their votes on the proposals set forth below. A ~~copy~~more ofdetailed ~~the~~description ~~press~~of ~~release~~each proposal is ~~furnished~~set ~~hereto~~forth asin ~~Exhibit~~the ~~99.1~~Company’s Proxy Statement filed with the Securities and isExchange ~~incorporated~~Commission ~~herein~~on byMarch ~~reference~~31, 2026 (the “2026 Proxy Statement”).

~~Item~~Proposal ~~7.01 Regulation~~1: To FDelect ~~Disclosure~~five nominees to the Board:

The ~~information~~Company’s ~~contained~~stockholders inelected ~~Item~~the ~~2.02~~five ispersons ~~incorporated~~listed ~~herein~~below byas ~~reference~~directors, each to hold office until the Company’s 2027 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal. The final voting results are as follows:

The information in Items 2.02 and 7.01 of this Current Report on Form 8-K, including Exhibit 99.1, is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, whether made before or after the date hereof, regardless of any general incorporation language in such filing.


Nominee	For	Withheld	Broker Non-Votes
Adam Sullivan	217,650,785	2,469,826	44,778,216
Jeff Booth	168,580,185	51,540,426	44,778,216
Elizabeth Crain	215,074,279	5,046,332	44,778,216
Yadin Rozov	213,054,408	7,066,203	44,778,216
Eric Weiss	168,947,230	51,173,381	44,778,216

~~Item 9.01 Financial~~Proposal ~~Statement~~2: ~~and~~To ~~Exhibits~~approve on a non-binding, advisory basis, the compensation of our named executive officers, as disclosed in the 2026 Proxy Statement:

~~(d)~~The ~~Exhibits~~Company’s stockholders approved, on a non-binding, advisory basis, the compensation of the Company’s named executive officers, as disclosed in the 2026 Proxy Statement. The final voting results are as follows:

ExhibitNo.		Description
For	Against	Abstain	Broker Non-Votes
99.1		Press Release dated May 6, 2026
138,785,477	79,166,695	2,168,439	44,778,216
99.2		Company Presentation dated May 6, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

Proposal 3: To ratify the appointment of KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026:

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. The final voting results are as follows:


For	Against	Abstain
262,833,296	313,161	1,752,370

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Core Scientific, Inc.
Dated: May 6, 2026
Dated: May 15, 2026
	By:	/s/ Todd M. DuChene
	Name:	Todd M. DuChene
	Title:	Chief Legal Officer and Chief Administrative Officer

Filing Compare · Core Scientific, Inc./tx